J&J: positive results for experimental RSV vaccine
(CercleFinance.com) - Johnson & Johnson's Janssen Pharmaceutical Companies announced on Saturday that its investigational respiratory syncytial virus (RSV) vaccine candidate showed 80% vaccine efficacy in adults 65 years and older in a Phase 2b study.
These results were described as very encouraging by Penny Heaton, head of global therapeutic research at Janssen Research & Development.
As the elderly are at high risk of severe complications from RSV, there is an urgent need for a vaccine to prevent the significant morbidity and mortality caused by the virus, she said.
Following these results, the company announces the launch of a phase 3 study to evaluate the efficacy, safety and immunogenicity of the investigational vaccine.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
These results were described as very encouraging by Penny Heaton, head of global therapeutic research at Janssen Research & Development.
As the elderly are at high risk of severe complications from RSV, there is an urgent need for a vaccine to prevent the significant morbidity and mortality caused by the virus, she said.
Following these results, the company announces the launch of a phase 3 study to evaluate the efficacy, safety and immunogenicity of the investigational vaccine.
Copyright (c) 2021 CercleFinance.com. All rights reserved.